A 58-year-old male from Delhi presents to the emergency department with a 5-day history of fever (39.2°C), dry cough, and progressive dyspnea. He reports loss of taste and smell for 2 days. On examination, oxygen saturation is 88% on room air, respiratory rate 28/min, and bilateral crackles are heard on auscultation. Chest X-ray shows bilateral ground-glass opacities with peripheral and lower lobe predominance. RT-PCR for SARS-CoV-2 from nasopharyngeal swab is positive. Laboratory findings: D-dimer 2.8 µg/mL (normal <0.5), ferritin 580 ng/mL (normal <200), IL-6 elevated at 85 pg/mL. Which of the following best explains the pathophysiology of his respiratory compromise and hypercoagulability?

Explanation

## Pathophysiology of COVID-19 Severity ### Mechanism of Respiratory Compromise **Key Point:** SARS-CoV-2 directly infects alveolar epithelial cells (type I and II pneumocytes) via ACE2 receptor binding, causing cytopathic injury and inflammatory cell infiltration. 1. **Viral entry and replication:** The spike (S) protein binds ACE2 receptors on respiratory epithelium, leading to cell lysis and release of viral particles. 2. **Inflammatory cascade:** Infected cells release damage-associated molecular patterns (DAMPs) and pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), recruiting macrophages and neutrophils. 3. **Alveolar-capillary barrier disruption:** Endothelial and epithelial damage increases vascular permeability, causing pulmonary edema and impaired gas exchange → ground-glass opacities on imaging. ### Hypercoagulability Mechanism **High-Yield:** SARS-CoV-2 induces a prothrombotic state through multiple mechanisms: | Mechanism | Effect | |-----------|--------| | **Endothelial dysfunction** | Virus infects endothelial cells; loss of anticoagulant surface properties | | **Platelet activation** | Elevated IL-6 and TNF-α activate platelets; direct viral interaction with megakaryocytes | | **Tissue factor upregulation** | Monocytes and macrophages express TF; extrinsic pathway activation | | **Complement activation** | Alternative and lectin pathways activated; C5a-mediated inflammation | | **Impaired fibrinolysis** | Elevated PAI-1 (plasminogen activator inhibitor-1) suppresses thrombin-activatable fibrinolysis inhibitor | **Clinical Pearl:** Elevated D-dimer and ferritin are markers of severity and correlate with thrombotic complications (DVT, PE, stroke) and mortality in COVID-19. ### Why This Patient's Findings Fit - **Anosmia/ageusia:** Direct viral invasion of olfactory epithelium and taste receptors (ACE2-expressing cells). - **Bilateral ground-glass opacities:** Diffuse alveolar damage with inflammatory infiltrate and edema. - **Elevated D-dimer, ferritin, IL-6:** Markers of severe systemic inflammation and thrombotic activation. - **Hypoxemia despite preserved lung mechanics early:** Ventilation-perfusion mismatch from microthrombi and inflammatory edema, not just mechanical obstruction. **Mnemonic: SARS-CoV-2 Pathology = DIVE:** - **D**irect viral injury (ACE2-mediated epithelial/endothelial damage) - **I**nflammatory cascade (cytokine storm) - **V**ascular thrombosis (endothelial dysfunction, platelet activation, TF upregulation) - **E**dema and barrier dysfunction (increased vascular permeability) [cite:Harrison 21e Ch 197]